China woos Taiwan’s first Wimbledon winner
Times of India But while the island was basking in her glory, Hsieh’s father, Hsieh Tze-lung, took the public by surprise when he said his daughter may give up her Taiwanese citizenship to represent China in exchange for an annual 10 million yuan ($1.63 million) … |
Research and Markets: PharmaPoint: Chronic Heart Failure – Global Drug … – Wall Street Journal
Research and Markets: PharmaPoint: Chronic Heart Failure – Global Drug …Wall Street JournalThe chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose marke…
Journal of Clinical Pharmacology Publishes First Clinical Experience with … – Wall Street Journal
Journal of Clinical Pharmacology Publishes First Clinical Experience with …Wall Street JournalIn March 2013, Trevena also presented the results of a Phase 2a study on the hemodynamic effects of TRV027 in patients with advanced systolic heart failure …
Kundapur: Catholic Sabha holds blood donation camp – Daijiworld.com
Kundapur: Catholic Sabha holds blood donation camp
Daijiworld.com Kundapur, Jul 8: Catholic Sabha Udupi Pradesh, Kundapur unit, Catholic women’s association, ICYM, Christian Women’s Association, St Franciscan Order and SVP, jointly organized blood donation camp on Sunday July 7 at Holy Rosary Church. “Donate … |
Presumed consent for organ donation makes a will and power of attorney essential – Access Legal from Shoosmiths
Presumed consent for organ donation makes a will and power of attorney essential
Access Legal from Shoosmiths There was some opposition to the changes from Christian churches and the Muslim and Jewish communities in Wales who wanted a ‘soft opt-out scheme’ to give deceased patients’ families a say in organ donation if their relative had not made their views on … |
Breast cancer drug everolimus fails to get NICE approval – OnMedica
The Guardian |
Breast cancer drug everolimus fails to get NICE approval
OnMedica The breast cancer drug everolimus (also called Afinitor) is not cost effective for the NHS. This is the recommendation from the National Institute for Health and Care Excellence (NICE) which today refused to give the green-light to everolimus … Novartis breast cancer drug Afinitor not cost effective for NHS, says draft …The Pharma Letter Breast cancer drug rulingITV News Novartis Cancer Drug Fails to Win U.K. Cost Agency’s NodBloomberg The Guardian –Guernsey Press and Star (subscription) all 27 news articles » |
A survey of TREM2 antibodies reveals neuronal but not microglial staining in … – 7thSpace Interactive (press release)
A survey of TREM2 antibodies reveals neuronal but not microglial staining in …
7thSpace Interactive (press release) Recently, two independent studies indicated a strong association between a rare rs75932628-T variant encoding non-functional R47H in the TREM2 gene and an increased risk for Alzheimer’s disease (AD). TREM2 expressed on monocytes/macrophages, … |
Are you talking about organ donation? – shropshirelive.com (press release)
Are you talking about organ donation?
shropshirelive.com (press release) It is important for hospital staff to know what the wishes of patients are in relation to organ donation so we encourage people to discuss their wishes with their family and consider putting their name on the Organ Donor Register.” Ben Cole, NHS Blood … |
Tanzania: Joy As Kidney Disease Cure in Sight – AllAfrica.com
Tanzania: Joy As Kidney Disease Cure in Sight
AllAfrica.com “We in the kidney disease world are excited at the prospect and for sure the public should remain hopeful as this would mean reducing the chances of dialysis and kidney transplantation,” she said. According to the research conducted in the University … |
Move to keep bin Laden files secret – Belfast Telegraph
Belfast TelegraphMove to keep bin Laden files secretBelfast TelegraphAt least 10 people have been killed and 12 others injured when a two-storey hotel collapsed in southern India, an official said. … Homeland star David Harewood has revealed that wat…